Did you mean: Alpha Kupesi
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority …
…, A Galustyan, J Hak, M Hoffmann, A Kupesiz… - The Lancet …, 2021 - thelancet.com
Background Dabigatran etexilate is a direct oral anticoagulant with potential to overcome
the limitations of standard of care in children with venous thromboembolism. The aims of this …
the limitations of standard of care in children with venous thromboembolism. The aims of this …
Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity
…, Ş Haskoloğlu, M Gökalp Bolkent, A Küpesiz… - Nature …, 2014 - nature.com
Primary immunodeficiency disorders enable identification of genes with crucial roles in the
human immune system. Here we study patients suffering from recurrent bacterial, viral and …
human immune system. Here we study patients suffering from recurrent bacterial, viral and …
Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis
…, C Klein, A Kulagin, A Kupesiz… - Blood, The Journal …, 2022 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment
for patients affected by Wiskott-Aldrich syndrome (WAS). Reported HSCT outcomes have …
for patients affected by Wiskott-Aldrich syndrome (WAS). Reported HSCT outcomes have …
[HTML][HTML] Hematopoietic cell transplantation in severe combined immunodeficiency: the SCETIDE 2006-2014 European cohort
…, A Ikinciogullari, K Kalwak, S Kansoy, A Kupesiz… - Journal of Allergy and …, 2022 - Elsevier
Background Hematopoietic stem cell transplantation (HSCT) represents a curative treatment
for patients with severe combined immunodeficiency (SCID), a group of monogenic immune …
for patients with severe combined immunodeficiency (SCID), a group of monogenic immune …
[HTML][HTML] Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial …
…, K Kavakli, B Antmen, I Sasmaz, A Kupesiz… - Journal of Thrombosis …, 2015 - Elsevier
Background BAY 81‐8973 is a new full‐length human recombinant factor VIII product
manufactured with technologies to improve consistency in glycosylation and expression to …
manufactured with technologies to improve consistency in glycosylation and expression to …
Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
…, S Robinson, Y Bertrand, A Kupesiz… - Bone marrow …, 2020 - nature.com
Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total
body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem …
body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem …
Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience
There is limited data about the long-term treatment outcome and prognosis of childhood acute
lymphoblastic leukemia (ALL) in developing countries. Our study was designed to assess …
lymphoblastic leukemia (ALL) in developing countries. Our study was designed to assess …
Gene therapy in haemophilia: literature review and regional perspectives for Turkey
Haemophilia is an X-linked lifelong congenital bleeding disorder that is caused by
insufficient levels of factor VIII (FVIII; haemophilia A) or factor IX (FIX; haemophilia B) and …
insufficient levels of factor VIII (FVIII; haemophilia A) or factor IX (FIX; haemophilia B) and …
Tissue plasminogen activator induced fibrinolysis: standardization of method using thromboelastography
A Kupesiz, M Rajpurkar, I Warrier… - Blood Coagulation & …, 2010 - journals.lww.com
Fibrinolysis is a complex physiological process that involves the interaction of several
anticoagulant proteins. Defects of the fibrinolytic system are extremely difficult to diagnose and …
anticoagulant proteins. Defects of the fibrinolytic system are extremely difficult to diagnose and …
Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience
We report the national data on the outcomes of hematopoietic stem cell transplantation (HSCT)
for thalassemia major (TM) patients in Turkey on behalf of the Turkish Pediatric Stem Cell …
for thalassemia major (TM) patients in Turkey on behalf of the Turkish Pediatric Stem Cell …
Did you mean to search for: Alpha Kupesi
